{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:24:01Z","timestamp":1774538641107,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011762","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000}}],"reference-count":281,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011762.pub2","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:48:50Z","timestamp":1737960530000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair"],"prefix":"10.1002","volume":"2025","author":[{"given":"Carlos A","family":"Salazar","sequence":"additional","affiliation":[{"name":"Epidemiology Unit. Faculty of Medicine; Universidad Peruana Cayetano Heredia; Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan E","family":"Basilio Flores","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Universidad Nacional Mayor de San Marcos; Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"German","family":"Malaga","sequence":"additional","affiliation":[{"name":"Center for Global Health; Universidad Peruana Cayetano Heredia; Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana N","family":"Malasquez","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia; Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine; Indiana University School of Medicine; Indianapolis USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"10.1002\/14651858.CD011762.pub2-BIB0001|cit1","unstructured":"A phase 3 randomized, double-blind, active-controlled (Enoxaparin), parallel group, multi-center study to evaluate the safety and efficacy of oral apixaban in subjects undergoing elective total knee replacement surgery trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-002161-39-DK"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1182\/blood.V112.11.31.31","article-title":"Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial","volume":"112","author":"Lassen","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0004|cit4","unstructured":"Study of apixaban for the prevention of thrombosis-related events following knee replacement surgery clinicaltrials.gov\/show\/NCT00371683"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0006|cit6","unstructured":"A phase 3, randomized, double-blind, active-controlled (Enoxaparin 40 mg QD), parallel-group, multi-center study to evaluate the safety and efficacy of apixaban in subjects undergoing elective total knee replacement surgery who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-006896-19-AT"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011762.pub2-BIB0007|cit7","first-page":"LB","article-title":"The ADVANCE-2 Study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement","volume":"7","author":"Lassen","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9717","key":"10.1002\/14651858.CD011762.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0009|cit9","unstructured":"Study of an investigational drug for the prevention of thrombosis-related events following knee replacement surgery clinicaltrials.gov\/show\/NCT00452530"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jth.12109","article-title":"Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups","volume":"11","author":"Pineo","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0012|cit12","first-page":"257","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials","volume":"94","author":"Raskob","year":"2012","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0013|cit13","unstructured":"A phase 3, randomized, double-blind, active-controlled, parallel-group, multi-center study to evaluate the safety and efficacy of apixaban in subjects undergoing elective total hip replacement surgery trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-005351-14-DE"},{"issue":"26","key":"10.1002\/14651858.CD011762.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0015|cit15","unstructured":"Study of an investigational drug for the prevention of thrombosis-related events following hip replacement surgery (ADVANCE-3) clinicaltrials.gov\/ct2\/show\/NCT00423319"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jth.12109","article-title":"Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups","volume":"11","author":"Pineo","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0018|cit18","first-page":"257","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials","volume":"94","author":"Raskob","year":"2012","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0020|cit20","unstructured":"New oral anticoagulant therapy for the prevention of blood clots following hip or knee replacement surgery clinicaltrials.gov\/show\/NCT00074828"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0021|cit21","unstructured":"A phase 2 randomized, double blinded (BMS-562247 and enoxaparin), active-controlled (enoxaparin and warfarin), parallel-arm, dose response study of the oral factor Xa Inhibitor BMS-562247 in subjects undergoing elective total knee replacement surgery trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-001128-19-DK"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD011762.pub2-BIB0022|cit22","first-page":"173","article-title":"A phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of Apixaban, a new oral Factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery","volume":"108","author":"Lassen","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD011762.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0024|cit24","unstructured":"BMS-562247 in subjects undergoing elective total knee replacement surgery clinicaltrials.gov\/show\/NCT00097357"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/23094990211042674","article-title":"Application of thromboelastography in comparing coagulation difference of rivaroxaban and enoxaparin for thromboprophylaxis after total hip arthroplasty","volume":"29","author":"Bai","year":"2021","journal-title":"Journal of Orthopaedic Surgery"},{"issue":"3S","key":"10.1002\/14651858.CD011762.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1213\/01.ane.0000492901.07918.38","article-title":"The role of the psycho-emotional state in hip replacement-associated thrombosis in the presence of modern thromboprophylaxis","volume":"123","author":"Berezhnyak","year":"2016","journal-title":"Anesthesia and Analgesia"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3969\/j.issn.2095-4344.1029","article-title":"Anticoagulant effect of low-molecular-weight heparin versus rivaroxaban after arthroplasty assessed by thromboelastography","volume":"23","author":"Changchun","year":"2019","journal-title":"Chinese Journal of Tissue Engineering Research"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0028|cit28","first-page":"4077","article-title":"Efficacy and safety of rivaroxaban in preventing deep venous thromboembolism after major orthopedic operations","volume":"9","author":"Chen","year":"2016","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011762.pub2-BIB0029|cit29","first-page":"2541","article-title":"Erratum to: An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery (Journal of Thrombosis and Haemostasis, (2013), 11, 8, (1503-1510), 10.1111\/jth.12328)","volume":"16","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V112.11.980.980","article-title":"An adaptive-design dose-ranging study of PD 0348292, a new oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery [abstract no. 980]","volume":"112","author":"Cohen","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD011762.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/jth.12328","article-title":"An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery","volume":"11","author":"Cohen","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0032|cit32","unstructured":"A phase 2B, randomised, multicenter, dose-ranging study assessing the safety and efficacy of PD 0348292 in the prevention of venous thromboembolic events (VTE) in subjects undergoing an elective, unilateral total knee replacement trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-005179-14-ES"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0033|cit33","unstructured":"Evaluation of PD 0348292 for preventing blood clots in the lungs or deep leg veins of patients after knee surgery clinicaltrials.gov\/show\/NCT00306254"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0034|cit34","unstructured":"DARINA. A randomized pilot study comparing the safety of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after knee arthroplasty surgery trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-003556-39-NL"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0035|cit35","unstructured":"Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the prevention of venous thromboembolism after knee arthroplasty surgery (DARINA) clinicaltrials.gov\/show\/NCT01431456"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"e040336","DOI":"10.1136\/bmjopen-2020-040336","article-title":"Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study","volume":"11","author":"Van der Veen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0037|cit37","unstructured":"Factor Xa Inhibitor, PRT054021, against enoxaparin for the prevention of venous thromboembolic events (EXPERT) clinicaltrials.gov\/show\/NCT00375609"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0039|cit39","unstructured":"Turpie AG Gent M Bauer K Davidson BL Fisher W Huo M Evaluation of the factor xa (fxa) inhibitor, prt054021 (prt021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT) XXIst Congress of the International Society on Thrombosis and Haemostasis Geneva 2007 Abstract no: P T-652"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1076029612457810","article-title":"Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies","volume":"20","author":"Fuji","year":"2014","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0042|cit42","unstructured":"Prevention of venous thromboembolism in patients undergoing elective total hip replacement surgery clinicaltrials.gov\/show\/NCT00913120"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1076029612457810","article-title":"Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies","volume":"20","author":"Fuji","year":"2014","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0044|cit44","unstructured":"Prevention of venous thromboembolism in patients undergoing elective total knee replacement surgery clinicaltrials.gov\/show\/NCT00917254"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.34172\/cjmb.2022.23","article-title":"Comparison of the effects of injectable enoxaparin with oral rivaroxaban in deep vein thrombotic prophylaxis in patients with femoral peritrochanteric rracture: a randomised clinical trial","volume":"9","author":"Hoseinzadeh","year":"2022","journal-title":"Crescent Journal of Medical and Biological Sciences"},{"issue":"13","key":"10.1002\/14651858.CD011762.pub2-BIB0046|cit46","first-page":"02023","article-title":"Different anticoagulant drugs during knee joint replacement: changes of hemorheology","volume":"19","author":"Hu","year":"2015","journal-title":"Chinese Journal of Tissue Engineering Research"},{"issue":"30","key":"10.1002\/14651858.CD011762.pub2-BIB0047|cit47","first-page":"5440","article-title":"Efficacy and safety of rivaroxaban in the prevention of deep vein thrombosis after hip arthroplasty","volume":"17","author":"Hui","year":"2013","journal-title":"Chinese Journal of Tissue Engineering Research"},{"issue":"7","key":"10.1002\/14651858.CD011762.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3349\/ymj.2019.60.7.626","article-title":"Comparison of apixaban and low molecular weight heparin in preventing deep venous thrombosis after total knee arthroplasty in older adults","volume":"60","author":"Jiang","year":"2019","journal-title":"Yonsei Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD011762.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1590\/S0102-36162008000800002","article-title":"Comparative study between rivaroxaban and enoxaparin in deep venous thromboembolism prophylaxis in patients submitted to total hip arthroplasty","volume":"43","author":"Kanan","year":"2008","journal-title":"Revista Brasileira de Ortopedia"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00590-018-2307-7","article-title":"Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty","volume":"29","author":"Karampinas","year":"2019","journal-title":"European Journal of Orthopaedic Surgery & Traumatology"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0051|cit51","unstructured":"Assessment of microbleeding after prophylaxis with enoxaparin or rivaroxaban against venous thromboembolic disease following hip and knee surgery (PREVENT) anzctr.org.au\/ACTRN12609000762257.aspx"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Khalafallah AA Assessment of post-operative bleeding and venous thromboembolism after initial 24-hour intermittent pneumatic calf compression followed by rivaroxaban versus enoxaparin in elective hip and knee arthroplasty LANCET Haematology (Manuscript draft, not peer reviewed) 2018","DOI":"10.2139\/ssrn.3276427"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011762.pub2-BIB0053|cit53","first-page":"21","article-title":"The PREVENT trial-prevention of venous thromboembolism with enoxaparin vs rivaroxaban following hip and knee replacement surgeries","volume":"42","author":"Singh","year":"2012","journal-title":"Internal Medicine Journal"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/th15-07-0527","article-title":"Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty","volume":"115","author":"Kim","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bcp.14959","article-title":"Apixaban or enoxaparin: which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients?","volume":"88","author":"Kunal","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0056|cit56","unstructured":"Lassen MR Davidson BL Gallus A Pineo GF Ansell J Deitchman D A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery Blood 2003 15a Abstract 41"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0057|cit57","unstructured":"Randomized, double-blind, parallel-group, active-controlled, dose-confirmatory bridging study of rivaroxaban (BAY59-7939) 5 to 10 mg once-daily regimen with a reference drug of enoxaparin in the prevention of venous thromboembolism in patients undergoing elective total hip replacement clinicaltrials.gov\/ct2\/show\/NCT01205932"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0058|cit58","unstructured":"Randomized, double-blind, parallel-group, active-controlled, dose-confirmatory bridging study of rivaroxaban (BAY59-7939) 5 to 10 mg once-daily regimen with a reference drug of enoxaparin in the prevention of venous thromboembolism in patients undergoing elective total knee replacement clinicaltrials.gov\/ct2\/show\/NCT01206972"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","article-title":"Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"120","author":"Eriksson","year":"2007","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0060|cit60","unstructured":"ODiXahip - a phase IIa dose escalating proof of principle trial clinicaltrials.gov\/show\/NCT00839826"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0062|cit62","first-page":"Abstract number","article-title":"Prevention of venous thromboembolism with an oral, direct factor Xa inhibitor \u2013 BAY 59-7939 \u2013 in elective hip replacement: a dose-ranging study","volume":"3","author":"Eriksson","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH07-01-0055","article-title":"Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies","volume":"97","author":"Fisher","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0064|cit64","first-page":"453","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0066|cit66","unstructured":"Dose-ranging study of BAY 59-7939 on the prevention of VTE in patients undergoing elective total hip replacement clinicaltrials.gov\/show\/NCT00398905"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0067|cit67","unstructured":"Controlled, double-blind, randomized, dose-ranging study of once-daily regimen of BAY59-7939 in the prevention of VTE in patients undergoing elective total hip replacement - ODIXaHIP-OD trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-001341-14-DK"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"Abstract 280","DOI":"10.1182\/blood.V106.11.280.280","article-title":"Prevention of venous thromboembolism after total hip replacement with once-daily BAY 59-7939 - an oral, direct factor Xa inhibitor","volume":"106","author":"Eriksson","year":"2005","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD011762.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0070|cit70","first-page":"453","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0071|cit71","unstructured":"Dose-ranging study of once-daily regimen of BAY 59-7939 in the prevention of VTE in patients undergoing elective total hip replacement clinicaltrials.gov\/show\/NCT00396786"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH07-01-0055","article-title":"Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies","volume":"97","author":"Fisher","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0074|cit74","unstructured":"An oral, direct factor Xa inhibitor, BAY59-7939, for prophylaxis against venous thromboembolism after total knee replacement: a dose-ranging study clinicaltrials.gov\/show\/NCT00402467"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0075|cit75","first-page":"Abstract number","article-title":"An oral, direct factor Xa inhibitor \u2013 BAY 59-7939 \u2013 for prophylaxis against venous thromboembolism after total knee replacement: a dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0077|cit77","first-page":"Abstract 1865","article-title":"YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study","volume":"106","author":"Eriksson","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD011762.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0079|cit79","unstructured":"Direct factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open label enoxaparin (Study no. 150-CL-008) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-002457-41-AT"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0081|cit81","unstructured":"Factor Xa inhibitor YM150 for the prevention of blood clot formation in veins after scheduled hip replacement (ONYX-2) clinicaltrials.gov\/show\/NCT00353678"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0082|cit82","unstructured":"Protocol for phase IIb Study of YM150. A randomized, double-blind, double-dummy, parallel group study to compare YM150 bid and qd doses and enoxaparin for prevention of venous thromboembolism in subjects undergoing elective hip replacement surgery. A phase IIb study to evaluate the efficacy and safety of YM150 compared to enoxaparin in subjects undergoing elective hip replacement surgery - ONYX-3 trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008-004416-13-AT"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0083|cit83","first-page":"213","article-title":"Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIB dose confirmation study (ONYX-3)","volume":"111","author":"Eriksson","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0084|cit84","unstructured":"A study evaluating efficacy and safety of YM150 compared to enoxaparin in subjects undergoing hip replacement surgery clinicaltrials.gov\/show\/NCT00902928"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3944\/AOTT.2015.14.0219","article-title":"Comparison of switch-therapy modalities (enoxaparin to rivaroxaban\/dabigatran) and enoxaparin monotherapy after hip and knee replacement","volume":"49","author":"\u00d6zler","year":"2015","journal-title":"Acta Orthopaedica et Traumatologica Turcica"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2309499020938865","article-title":"Incidence of silent venous thromboembolism after total hip arthroplasty: a comparison of rivaroxaban and enoxaparin","volume":"28","author":"Rahman","year":"2020","journal-title":"Journal of Orthopaedic Surgery"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0087|cit87","unstructured":"A phase IIB, randomized, parellel group, double blind, double dummy, multi-center, multi national, multi-dose study of DU-176b compared to dalteparin in patients undergoing elective unilateral total hip replacement https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-000758-29-GB"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0088|cit88","unstructured":"A study of DU-176b in preventing blood clots after hip replacement surgery clinicaltrials.gov\/show\/NCT00398216"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH10-02-0142","article-title":"Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study","volume":"104","author":"Raskob","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0090|cit90","unstructured":"REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12606000068561"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0091|cit91","unstructured":"RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement - RECORD 1 trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-004351-35-SE"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"Abstract no: 6","DOI":"10.1182\/blood.V110.11.6.6","article-title":"Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial","volume":"110","author":"Eriksson","year":"2007","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0093|cit93","first-page":"82","article-title":"Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1","volume":"141","author":"Eriksson","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"26","key":"10.1002\/14651858.CD011762.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0095|cit95","first-page":"636","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0096|cit96","first-page":"A15","article-title":"Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1","volume":"36","author":"Haas","year":"2008","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0097|cit97","first-page":"652","article-title":"Enoxaparin versus Dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials","volume":"3","author":"Huisman","year":"2010","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0098|cit98","first-page":"1573","article-title":"The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme","volume":"94","author":"Lassen","year":"2012","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/VHRM.S54714","article-title":"Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty","volume":"10","author":"Levitan","year":"2014","journal-title":"Vascular Health and Risk Management"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0100|cit100","unstructured":"Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin clinicaltrials.gov\/ct2\/show\/NCT00329628"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11239-020-02078-8","article-title":"Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism","volume":"50","author":"Reinecke","year":"2020","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/aas.12069","article-title":"Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin)","volume":"57","author":"Rosencher","year":"2013","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0105|cit105","unstructured":"RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, double-blind, randomized study of BAY59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement - Record 2 https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-004691-20-GB"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0106|cit106","first-page":"636","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0107|cit107","first-page":"A15","article-title":"A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short-term subcutaneous enoxaparin after total hip replacement: RECORD2","volume":"36","author":"Kakkar","year":"2008","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"Abstract no: 30","DOI":"10.1182\/blood.V110.11.307.307","article-title":"Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: the RECORD2 Trial","volume":"110","author":"Kakkar","year":"2007","journal-title":"Blood"},{"issue":"9632","key":"10.1002\/14651858.CD011762.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0110|cit110","first-page":"65","article-title":"RECORD2: extended thromboprophylaxis with rivaroxaban versus short-term thromboprophylaxis with enoxaparin after total hip replacement","volume":"141","author":"Kakkar","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0111|cit111","first-page":"1573","article-title":"The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme","volume":"94","author":"Lassen","year":"2012","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/VHRM.S54714","article-title":"Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty","volume":"10","author":"Levitan","year":"2014","journal-title":"Vascular Health and Risk Management"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0113|cit113","first-page":"15","article-title":"Extended thrombosis prophylaxis with rivaroxaban in comparison to short-term thrombosis prophylaxis with Enoxaparin after total hip replacement: the RECORD2 study","volume":"103","author":"Mouret","year":"2008","journal-title":"Medizinische Klinik"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0114|cit114","unstructured":"Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement clinicaltrials.gov\/show\/NCT00332020"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11239-020-02078-8","article-title":"Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism","volume":"50","author":"Reinecke","year":"2020","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/aas.12069","article-title":"Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin)","volume":"57","author":"Rosencher","year":"2013","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0119|cit119","unstructured":"REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elective total knee replacement - RECORD 3 trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-004620-40-SE"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0120|cit120","first-page":"636","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0121|cit121","first-page":"652","article-title":"Enoxaparin versus Dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials","volume":"3","author":"Huisman","year":"2010","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"26","key":"10.1002\/14651858.CD011762.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0123|cit123","first-page":"1573","article-title":"The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme","volume":"94","author":"Lassen","year":"2012","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0124|cit124","unstructured":"Lassen MR Turpie AG Rosencher N Borris LC Ageno W Lieberman JR Rivaroxaban: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in total knee replacement surgery - results of the RECORD 3 study XXIst Congress of the International Society on Thrombosis and Haemostasis 2007 Jul 6-12 Geneva 2007"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0125|cit125","first-page":"50","article-title":"The oral, direct factor Xa inhibitor rivaroxaban vs enoxaparin for prevention of venous thromboembolism after total knee replacement: RECORD3","volume":"141","author":"Lassen","year":"2008","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/VHRM.S54714","article-title":"Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty","volume":"10","author":"Levitan","year":"2014","journal-title":"Vascular Health and Risk Management"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0127|cit127","unstructured":"Regulation of coagulation in orthopedic surgery to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). A study of BAY 59-7939 in the prevention of VTE in subjects undergoing elective total knee replacement clinicaltrials.gov\/show\/NCT00361894"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11239-020-02078-8","article-title":"Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism","volume":"50","author":"Reinecke","year":"2020","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/aas.12069","article-title":"Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin)","volume":"57","author":"Rosencher","year":"2013","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0132|cit132","unstructured":"Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet\/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial www.bayer.ca\/"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0133|cit133","unstructured":"RECORD 4 Study: REgulation of Coagulation in ORthopedic surgery to prevent DVT and PE; a controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elective total knee replacement - RECORD 4 who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-002402-60-SE"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0134|cit134","first-page":"652","article-title":"Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials","volume":"3","author":"Huisman","year":"2010","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0135|cit135","first-page":"1573","article-title":"The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme","volume":"94","author":"Lassen","year":"2012","journal-title":"Journal of Bone and Joint Surgery: British volume"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/VHRM.S54714","article-title":"Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty","volume":"10","author":"Levitan","year":"2014","journal-title":"Vascular Health and Risk Management"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0137|cit137","unstructured":"Regulation of coagulation in orthopedic surgery to prevent deep vein thromboembolism (DVT) and pulmonary embolism (PE). A study of BAY59-7939 in the prevention of venous thrombo embolism (VTE) in subjects undergoing elective total knee replacement clinicaltrials.gov\/show\/NCT00362232"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.thromres.2012.02.011","article-title":"Dabigatran, rivaroxaban and apixaban versus enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials","volume":"130","author":"Nieto","year":"2012","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11239-020-02078-8","article-title":"Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism","volume":"50","author":"Reinecke","year":"2020","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/aas.12069","article-title":"Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin)","volume":"57","author":"Rosencher","year":"2013","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood.V112.11.35.35","article-title":"Once-daily oral rivaroxaban compared with subcutaneous enoxaparin every 12 Hours for thromboprophylaxis after total knee replacement: RECORD4","volume":"112","author":"Turpie","year":"2008","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0142|cit142","first-page":"A14","article-title":"Rivaroxaban - an oral, direct factor xa inhibitor - versus enoxaparin for thromboprophylaxis after total knee replacement: RECORD4, A phase III study","volume":"36","author":"Turpie","year":"2008","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"9676","key":"10.1002\/14651858.CD011762.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"135","author":"Fuji","year":"2014","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0146|cit146","first-page":"109","article-title":"Efficacy and safety of edoxaban for the prevention of venous thromboembolism after total knee or hip arthroplasty: A pooled analysis of two pivotal studies vs. enoxaparin","volume":"9","author":"Fuji","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0147|cit147","first-page":"109","article-title":"Efficacy and safety of edoxaban for the prevention of venous thromboembolism after total knee or hip arthroplasty: a pooled analysis of two pivotal studies vs. enoxaparin","volume":"9","author":"Fuji","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0148|cit148","unstructured":"Fuji T Wang CJ Fujita S Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the Stars E-3 Trial [abstract OC297] 21st International Congress of Thrombosis Milan, Italy 2010"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0149|cit149","unstructured":"DU-176b phase 3 clinical study (venous thromboembolism) -randomized double-blind study of DU-176b in patients undergoing total knee arthroplasty with enoxaparin as an active control trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-090727"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0150|cit150","unstructured":"A phase 3 study of DU-176b, prevention of venous thromboembolism in patients after total knee arthroplasty clinicaltrials.gov\/show\/NCT01181102"},{"issue":"12","key":"10.1002\/14651858.CD011762.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.arth.2014.05.029","article-title":"Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan","volume":"29","author":"Fuji","year":"2014","journal-title":"Journal of Arthroplasty"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0152|cit152","unstructured":"Fuji T Wang CJ Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose-finding study 51st ASH Annual Meeting and Exposition New Orleans 2012"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0153|cit153","unstructured":"DU-176b Phase IIb clinical study (venous thromboembolism): Japan-Taiwan multicenter randomized double-blind dose-finding study using Enoxaparin as a reference in patients undergoing total hip replacement trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-090827"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0154|cit154","unstructured":"A phase 2b study of DU-176b, prevention of venous thromboembolism in patients after total hip arthroplasty clinicaltrials.gov\/show\/NCT01203098"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.thromres.2014.03.009","article-title":"Safety and efficacy of edoxaban in patients undergoing hip fracture surgery","volume":"133","author":"Fuji","year":"2014","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0156|cit156","unstructured":"DU-176b phase III clinical study (venous thromboembolism) - a multicenter, tandomized, unblinded study of DU-176b in patients undergoing hip fracture surgery with enoxaparin as a reference trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-090798"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0157|cit157","unstructured":"Study of DU-176b, prevention of venous thromboembolism in patients after hip fracture surgery clinicaltrials.gov\/show\/NCT01181141"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","article-title":"Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V","volume":"13","author":"Fuji","year":"2015","journal-title":"Thrombosis Journal"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"Abstract No. 33","DOI":"10.1182\/blood.V116.21.3320.3320","article-title":"Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: Stars J-V trial","volume":"116","author":"Fuji","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0160|cit160","first-page":"109","article-title":"Efficacy and safety of edoxaban for the prevention of venous thromboembolism after total knee or hip arthroplasty: a pooled analysis of two pivotal studies vs. enoxaparin","volume":"9","author":"Fuji","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0161|cit161","first-page":"109","article-title":"Efficacy and safety of edoxaban for the prevention of venous thromboembolism after total knee or hip arthroplasty: a pooled analysis of two pivotal studies vs. enoxaparin","volume":"9","author":"Fuji","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0162|cit162","unstructured":"DU-176b phase III clinical study (venous thromboembolism) randomized double-blind study of DU-176b in patients undergoing total hip arthroplasty with enoxaparin as an active control who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-090771"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0163|cit163","unstructured":"A study of DU-176b, prevention of venous thromboembolism in patients after total hip arthroplasty clinicaltrials.gov\/show\/NCT01181167"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0164|cit164","unstructured":"A comparative study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-INR-17010495"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.biopha.2017.05.107","article-title":"A RCT study of rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture","volume":"92","author":"Tang","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0166|cit166","unstructured":"Comparison of blood loss following total hip arthroplasty with the use of three thromboprophylactic regimes: dabigatran, enoxaparin and rivaroxaban clinicaltrials.gov\/show\/NCT02085824"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0167|cit167","first-page":"S61","article-title":"No difference in blood loss following total hip replacement with three thromboprophylactic regimes (enoxaparin, dabigatran or rivaroxaban) - results from a randomized, double-blind clinical trial","volume":"25","author":"Wasko","year":"2015","journal-title":"HIP International"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0168|cit168","unstructured":"Efficacy and safety of TAK-442 in subjects undergoing total knee replacement clinicaltrials.gov\/show\/NCT00641732"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1160\/TH10-05-0273","article-title":"A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery","volume":"104","author":"Weitz","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0170|cit170","first-page":"11","article-title":"The efficacy and safety of rivaroxaban in preventing deep vein thrombosis after hip replacement","volume":"82","author":"Wing","year":"2020","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"704","DOI":"10.12659\/MSM.900059","article-title":"Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: a pilot study","volume":"23","author":"Xie","year":"2017","journal-title":"Medical Science Monitor"},{"issue":"15","key":"10.1002\/14651858.CD011762.pub2-BIB0172|cit172","first-page":"2303","article-title":"Rivaroxaban and low molecular heparin in prevention of deep venous thrombosis and blood loss after total hip arthroplasty in elderly patients","volume":"22","author":"Yun-Fei","year":"2018","journal-title":"Chinese Journal of Tissue Engineering Research"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0173|cit173","unstructured":"Effectiveness of tranexamic acid combined with different antithrombotic agents in total knee arthroplasty chinese clinical trial registry 2023"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0174|cit174","first-page":"1","article-title":"Efectiveness of diferent antithromboticagents in combination with tranexamic acid for venous thromboembolism prophylaxisand blood management after total kneereplacement: a prospective randomized study","volume":"24","year":"2023","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"7","key":"10.1002\/14651858.CD011762.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","article-title":"Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty","volume":"25","author":"Zou","year":"2014","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"Article ID 2945","DOI":"10.1155\/2021\/2945978","article-title":"Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep VenousThrombosis in Arthroplasty","volume":"2021","author":"\u00c7i\u00e7ek","year":"2021","journal-title":"Emergency Medicine International"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0177|cit177","unstructured":"Xarelto in the prevention of venous thromboembolism after knee or hip replacement surgery trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2011\/07\/001881"},{"issue":"36","key":"10.1002\/14651858.CD011762.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"e22028","DOI":"10.1097\/MD.0000000000022028","article-title":"Effect of 3 different anticoagulants on hidden blood loss during total hip arthroplasty after tranexamic acid","volume":"99","author":"Deng","year":"2020","journal-title":"Medicine"},{"issue":"15","key":"10.1002\/14651858.CD011762.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2008.03.007","article-title":"SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose ranging study in elective total hip replacement surgery) study","volume":"51","author":"Lassen","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"490A","key":"10.1002\/14651858.CD011762.pub2-BIB0180|cit180","first-page":"Abstract 2110","article-title":"The PENTHIFRA Study. Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) after hip fracture surgery","volume":"96","author":"Eriksson","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/j.1538-7836.2010.04021.x","article-title":"A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty","volume":"8","author":"Fuji","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3923\/ijp.2018.1.8","article-title":"Comparing the efficacy, safety and cost of the anticoagulants: rivaroxaban and nadroparin in hip replacement surgery","volume":"14","author":"Jiang","year":"2018","journal-title":"International Journal of Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood.V110.11.1874.1874","article-title":"Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study","volume":"110","author":"Kwong","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.V112.11.1289.1289","article-title":"Rivaroxaban for prevention of venous thromboembolism after total knee replacement: impact on healthcare costs based on the RECORD4 study","volume":"112","author":"Kwong","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0185|cit185","first-page":"A45","article-title":"Thrombin generation during major orthopedic surgery: rivaroxaban versus enoxaparin for thromboprophylaxis","volume":"31","author":"Velik-Salchner","year":"2011","journal-title":"Hamostaseologie"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1160\/TH13-01-0066","article-title":"Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial","volume":"109","author":"Verhamme","year":"2013","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MBC.0000000000000786","article-title":"Low-molecular-weight heparin followed by rivaroxaban or not for the prevention of deep venous thromboembolism after total knee arthroplasty","volume":"30","author":"Zhou","year":"2019","journal-title":"Blood Coagulation and Fibrinolysis"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0188|cit188","first-page":"888","article-title":"Influence of enoxaparin and rivaroxaban on postoperative anticoagulation effect and bone metabolism indicators in elderly patients undergoing joint replacement","volume":"41","author":"Hu","year":"2022","journal-title":"Latin American Journal of Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0189|cit189","first-page":"856","article-title":"Comparison of effectiveness and safety for the apixaban and low-molecular-weight heparin in prevention of deep vein thrombosis after hip replacement","volume":"40","author":"Wang","year":"2021","journal-title":"Latin American Journal of Pharmacy"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0190|cit190","unstructured":"Wei C The study of the efficacy and safety of VTE prophylaxis with rivaroxaban following total hip replacement PLA Postgraduate Medical School 2008 CNKI:CDMD:1.2008.087675"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0191|cit191","unstructured":"Anti-coagulation effect of aspirin, LMWH and rivaroxaban after total hip arthroplasty:a prospective randomised control trial who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR1800016829"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0192|cit192","unstructured":"The effect of rivaroxaban and enoxaparin on the prophylaxis of venous thromboembolism trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20161121031003N4"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0193|cit193","unstructured":"Effectiveness of aspirin 80, aspirin 325, enoxaparin and rivoroxaban in prevention of coagulopathy after total knee arthroplasty who.int\/trialsearch\/Trial2.aspx?TrialID=IRCT20181128041784N1"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0194|cit194","unstructured":"Prevention of deep vein thrombosis in pre-trochanteric hip fracture en.irct.ir\/trial\/44128"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0195|cit195","unstructured":"A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000026819"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0196|cit196","unstructured":"Elucidation of individual difference factors in the pharmacokinetics and clinical effects of anticoagulants edoxaban and enoxasaparin [sic] who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000033422"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0197|cit197","unstructured":"Factor Xa inhibitor for prevention of venous thromboembolism in patients undergoing elective total knee replacement (PEARL-1) clinicaltrials.gov\/ct2\/show\/NCT00408239"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0198|cit198","unstructured":"Comparison of blood loss following total hip arthroplasty with the use of three thromboprophylactic regimes: dabigatran, enoxaparin and rivaroxaban https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT02085824\/"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0199|cit199","unstructured":"Prophylaxis of deep vein thrombosis following total hip arthroplasty clinicaltrials.gov\/ct2\/show\/NCT02379663"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0200|cit200","unstructured":"Safety and efficacy of TeaRx Xa factor direct inhibitor versus enoxaparin as a venous thromboembolic events (VTE) prevention following total knee replacement clinicaltrials.gov\/show\/NCT03088358"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0201|cit201","unstructured":"A multicenter randomized double-blind placebo-controlled prospective study to evaluate the safety and efficacy of the direct factor Xa inhibitor dimolegin (DD217) in prevention of venous thromboembolic complications during knee replacement https:\/\/clinicaltrials.gov\/study\/NCT05189002"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0202|cit202","unstructured":"Comparative effectiveness of pulmonary embolism prevention after hip and knee replacement (PEPPER) clinicaltrials.gov\/ct2\/show\/NCT02810704"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"e060000","DOI":"10.1136\/bmjopen-2021-060000","article-title":"Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol","volume":"12","author":"Eikelboom","year":"2022","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0204|cit204","unstructured":"Association of American Medical Colleges (AAMC) The Scientific Basis of Influence and Reciprocity: A Symposium (accessed June 5, 2015) 2008"},{"issue":"2 Supple","key":"10.1002\/14651858.CD011762.pub2-BIB0205|cit205","first-page":"e44S\u2013e88S","article-title":"Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th edition: ACCP Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"CHEST"},{"issue":"23","key":"10.1002\/14651858.CD011762.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"3898\u20133944","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Advances"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0883-5403(97)90131-5","article-title":"Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases","volume":"12","author":"Ansari","year":"1997","journal-title":"Journal of Arthroplasty"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","article-title":"Managing oral anticoagulant therapy","volume":"119","author":"Ansell","year":"2001","journal-title":"CHEST Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.jvca.2012.03.029","article-title":"Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors","volume":"26","author":"Augoustides","year":"2012","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"issue":"12 Suppl 3","key":"10.1002\/14651858.CD011762.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3949\/ccjm.84.s3.04","article-title":"Update on the management of venous thromboembolism","volume":"84","author":"Bartholomew","year":"2017","journal-title":"Cleveland Clinic Journal of Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11926-015-0498-z","article-title":"Using new oral anticoagulants in patients undergoing major orthopedic surgery","volume":"17","author":"Bass","year":"2015","journal-title":"Current Rheumatology Reports"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1026106915960","article-title":"Factor Xa - a pleuripotential protease","volume":"15","author":"Becker","year":"2003","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"8","key":"10.1002\/14651858.CD011762.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2017.3854","article-title":"Addressing bias and conflict of interest among biomedical researchers","volume":"17","author":"Bero","year":"2017","journal-title":"JAMA"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011762.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.arth.2009.06.002","article-title":"Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials","volume":"24","author":"Brown","year":"2009","journal-title":"Journal of Arthroplasty"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0217|cit217","first-page":"1","article-title":"Thromboprophylaxis with apixaban in patients undergoing major orthopedic surgery: meta-analysis and trial-sequential analysis","volume":"10","author":"Caldeira","year":"2017","journal-title":"Clinical Medicine Insights: Blood Disorders"},{"issue":"11","key":"10.1002\/14651858.CD011762.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2010","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1592\/phco.23.6.772.32190","article-title":"Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery","volume":"23","author":"Comp","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.290.2.252","article-title":"A social science perspective on gifts to physicians from industry","volume":"290","author":"Dana","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0221|cit221","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org\/handbook 2023"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1136\/bmj.o3071","article-title":"Rivaroxaban: Lancet opens investigation into anticlotting drug trial after BMJ report","volume":"379","author":"Demasi","year":"2022","journal-title":"BMJ"},{"issue":"13","key":"10.1002\/14651858.CD011762.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinte.162.13.1465","article-title":"Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes","volume":"162","author":"Douketis","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"629\u201334","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0225|cit225","unstructured":"European Medicines Evaluation Agency (EMEA) AstraZeneca withdraws its application for Ximelagatran 36-mg film-coated tablets http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/ximelagatran\/5782706en.pdf; 16 February 2006; London"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0226|cit226","unstructured":"European Medicines Evaluation Agency (EMEA) Questions and answers on withdrawal of the marketing application for ximelagatran AstraZeneca 36 mg film coated tablets http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/ximelagatran\/6046506en.pdf; 23 February 2006; London"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011762.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ocl.2020.06.002","article-title":"Allowed activities after primary total knee arthroplasty and total hip arthroplasty","volume":"51","author":"Fawaz","year":"2020","journal-title":"Orthopedic Clinics of North America"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0229|cit229","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004179.pub2","article-title":"Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair","author":"Forster","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011762.pub2-BIB0230|cit230","first-page":"e2S","article-title":"Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis, 9th edition: ACCP Guidelines.","volume":"141","author":"Garcia","year":"2012","journal-title":"CHEST"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0232|cit232","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"7650","key":"10.1002\/14651858.CD011762.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"G\u00f3mez-Outes","year":"2012","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0236|cit236","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000305","article-title":"Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures","author":"Handoll","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD011762.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0238|cit238","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0239|cit239","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011762.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"CHEST Journal"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","article-title":"Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis","volume":"2","author":"Ieko","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false 10.1371\/journal.pmed.0020124]","volume":"8","author":"Ioannidis","year":"2005","journal-title":"PLoS Med"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/0141076820914242.","article-title":"Sponsorship bias in clinical trials: growing menace or dawning realisation?","volume":"113","author":"Jefferson","year":"2020","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/sim.6342","article-title":"Statistical methods for dealing with publication bias in meta-analysis","volume":"34","author":"Jin","year":"2015","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jth.13566","article-title":"Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis","volume":"15","author":"Kapoor","year":"2017","journal-title":"Journal of Thrombosis and Haemostasia"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00264-013-2134-8","article-title":"Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations","volume":"38","author":"Kinov","year":"2014","journal-title":"International Orthopedics"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939 an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2474-14-177","article-title":"Symptomatic venous thromboembolism and mortality in orthopaedic surgery - an observational study of 45968 consecutive procedures","volume":"14","author":"Lapidus","year":"2013","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"8","key":"10.1002\/14651858.CD011762.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archinte.158.8.873","article-title":"The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group","volume":"158","author":"Leclerc","year":"1998","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0250|cit250","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.thromres.2015.02.008","article-title":"Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: a meta-analysis of 6 randomized clinical trials","volume":"135","author":"Ma","year":"2015","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1590\/1516-3180.2016.0019260216","article-title":"Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis","volume":"134","author":"Marcolino","year":"2016","journal-title":"Sao Paulo Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD011762.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-156-10-201205150-00421","article-title":"Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis","volume":"156","author":"Neumann","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"23726","DOI":"10.1038\/srep23726","article-title":"Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"6","author":"Ning","year":"2016","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14656566.2013.774374","article-title":"Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA","volume":"14","author":"Nutescu","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0256|cit256","first-page":"27","article-title":"Natural history of thromboembolic disease after total hip arthroplasty","volume":"333","author":"Clement","year":"1996","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0258|cit258","unstructured":"R Development Core Team The comprehensive R archive network https:\/\/cran.r-project.org"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0259|cit259","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"192\u20138","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clinical Epidemiology and Global Health"},{"issue":"16","key":"10.1002\/14651858.CD011762.pub2-BIB0261|cit261","first-page":"2153","article-title":"Clinical pharmacology of direct and indirect factor Xa inhibitors","volume":"70","author":"Rupprecht","year":"2010","journal-title":"Drugs"},{"issue":"4","key":"10.1002\/14651858.CD011762.pub2-BIB0262|cit262","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005981.pub2","article-title":"Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement","author":"Salazar","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"18","key":"10.1002\/14651858.CD011762.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011762.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0266|cit266","first-page":"40","article-title":"Meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Sch\u00fcnemann","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0268|cit268","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease. Second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"CHEST"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1302\/0301-620X.71B3.2785998","article-title":"Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients","volume":"71","author":"Stringer","year":"1989","journal-title":"Journal of Bone and Joint Surgery - British Volume"},{"issue":"31","key":"10.1002\/14651858.CD011762.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/bmj.326.7400.1180","article-title":"Diagnosis, investigation, and management of deep vein thrombosis","volume":"326","author":"Tovey","year":"2003","journal-title":"BMJ"},{"issue":"10368","key":"10.1002\/14651858.CD011762.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"P2047","DOI":"10.1016\/S0140-6736(22)02422-9","article-title":"Correspondence: Revisiting RECORD4","volume":"400","author":"Turpie","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011762.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.thromres.2011.01.016","article-title":"A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement","volume":"127","author":"Turun","year":"2011","journal-title":"Thrombosis Research"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5578\/tt.24153","article-title":"A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embolism","volume":"64","author":"T\u00fcrk","year":"2016","journal-title":"Tuberkuloz ve Toraks"},{"issue":"2","key":"10.1002\/14651858.CD011762.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.arth.2016.09.033","article-title":"Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis","volume":"32","author":"Venker","year":"2017","journal-title":"Journal of Arthroplasty"},{"issue":"5","key":"10.1002\/14651858.CD011762.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.yco.0000139974.45189.96","article-title":"Scientific integrity, fidelity and conflicts of interest","volume":"17","author":"Warner","year":"2004","journal-title":"Current Opinion in Psychiatry"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011762.pub2-BIB0278|cit278","first-page":"e120S\u2013e151S","article-title":"New antithrombotic drugs. Antithrombotic therapy and prevention of thrombosis, 9th edition: ACCP Guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"CHEST"},{"issue":"14","key":"10.1002\/14651858.CD011762.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archinte.158.14.1525","article-title":"Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty","volume":"158","author":"White","year":"1998","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011762.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.avsg.2012.06.010","article-title":"Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin","volume":"27","author":"Yoshida Rde","year":"2013","journal-title":"Annals of Vascular Surgery"},{"issue":"6","key":"10.1002\/14651858.CD011762.pub2-BIB0281|cit281","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011762","article-title":"Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair","author":"Salazar","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:38:32Z","timestamp":1774535912000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011762.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":281,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011762.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}